New Scientific Advisory Board Member
“John’s expertise in end-to-end drug development, especially for diabetes, will be invaluable as we progress our lead candidates into IND and clinical stages,” said Dr. Russell Dahl, Neurodon’s CEO. “John has a deep knowledge of working with regulatory agencies that will help us get to FIH studies in an expeditious manner. His expertise complements our […]
Neurodon Welcomes Brunde Broady to its Board of Directors
“We are excited to welcome Brunde to our board of directors. She brings decades of leadership experience in key areas critical to the growth of our business and vital to our future operations and strategy. Brunde’s expertise is especially valuable to Neurodon as an emerging company.” said Dr. Russell Dahl, Neurodon’s CEO, and founder. Brunde […]
Neurodon Receives Funding from Elevate Ventures
We’re excited to join Elevate’s portfolio This program is funded by the state of Indiana’s 21st Century Research & Technology Fund. Eligible Indiana-based companies that have received SBIR/STTR funding are eligible to apply for the program that provides 50% matching funds. “We’re excited to join the Elevate portfolio and are grateful for their support of […]
Neurodon Awarded Phase I NIH STTR Grant
The grant is funded by the National Institute on Aging (NIA), an institute of the NIH focused on aging and the primary Federal agency that funds Alzheimer’s disease research. The highly competitive STTR program funds joint research proposals from small business concerns that partner with nonprofit organizations such as universities. Neurodon’s university partner is Northwestern […]
Neurodon Scientists Validated a New Way to Halt Brain Cell Loss
Neurodon scientists have validated a new way to halt brain cell loss by ramping up a natural protective strategy called SUMOylation. SUMO is a small protein that the body attaches to other proteins to activate a protective strategy against cell death. However, in the disease state, the natural SUMOylation is insufficient to halt cell loss. […]